The Cold Spring Harbor Laboratory (CSHL) Cancer Center (www.cshl.edu/cancercenter) is a vibrant and dynamic cancer research center that strives for excellence. Researchers are committed to using a focused, multidisciplinary and collaborative approach to investigate the molecular cellular basis of human cancer with the goal of improving diagnosis and treatment of ail major forms ofthe disease. The CSHL Cancer Center is organized into three Scientific Programs. The Gene Expression &Cell Proliferation Program focuses on the regulation of gene expression, cell division cycle control and chromosome structure, comparing normal and cancer cells with a goal to identify new therapeutic targets. The Signal Transduction Program focuses on signal transduction pathways and cell architecture in normal and cancer cells, with a growing emphasis on tumor micro-environment and understanding mechanisms of resistance to targeted therapies. The Cancer Genetics Program focuses on understanding the genetic basis of cancer, tumor progression and discovery of new targets for therapy using innovative mouse models for human cancer. In addition, the CSHL Cancer Center supports ten scientific shared resources. These shared resources provide access to technologies, products, services and expertise that promote multidisciplinary interactions and collaborations among CSHL researchers and programs. Importantly, the shared resources increase productivity, provide economies of scale, decrease wasteful duplication of resources, maintain quality control, and facilitate access to expensive equipment and highly skilled technical services. In the last five years, the CSHL Cancer Center not only broke new ground in understanding cancer genetics and tumor biology, but also achieved its vision of a cancer discovery pipeline that integrates complex cellular processes and pathways in tumor cells with cell biology and biochemistry, human cancer genetics, RNAi technology and innovative animal models that mimic different subsets of human cancers. The pipeline has generated a wealth of pre-clinical data including information on new cancer genes and diagnostic tools, has identified potential new therapeutic targets, has investigated new biochemical pathways, and studied drug resistance mechanisms.

Public Health Relevance

Despite the discovery of targeted therapies that cure or control some cancer types, cancer remains one of the major causes of death in the US. The focus of the Cold Spring Harbor Laboratory Cancer Center is to understand the underlying genetic and cellular basis for the disease and to discover new, targeted and safe cancer therapies that are linked to the patient's tumor genetics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA045508-27S1
Application #
8917515
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-08-01
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
27
Fiscal Year
2014
Total Cost
$384,000
Indirect Cost
$184,000
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 33:527-541.e8
Stacchiotti, Silvia; Mir, Olivier; Le Cesne, Axel et al. (2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist 23:62-70
Hwang, Dong-Woo; Jaganathan, Anbalagan; Shrestha, Padmina et al. (2018) Chromatin-mediated translational control is essential for neural cell fate specification. Life Sci Alliance 1:e201700016
Goncalves, Marcus D; Hwang, Seo-Kyoung; Pauli, Chantal et al. (2018) Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci U S A 115:E743-E752
Biffi, Giulia; Oni, Tobiloba E; Spielman, Benjamin et al. (2018) IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov :
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
Aznarez, Isabel; Nomakuchi, Tomoki T; Tetenbaum-Novatt, Jaclyn et al. (2018) Mechanism of Nonsense-Mediated mRNA Decay Stimulation by Splicing Factor SRSF1. Cell Rep 23:2186-2198
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Lin, Kuan-Ting; Ma, Wai Kit; Scharner, Juergen et al. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res :
Fang, Han; Huang, Yi-Fei; Radhakrishnan, Aditya et al. (2018) Scikit-ribo Enables Accurate Estimation and Robust Modeling of Translation Dynamics at Codon Resolution. Cell Syst 6:180-191.e4

Showing the most recent 10 out of 380 publications